Scholarlink

Introduction <p>Lacrimal sac squamous cell carcinoma (LSSCC) is the most common tumor of the rare disease subsite of the nasolacrimal system. Circulating tumor DNA (ctDNA) has emerged as a biomarker for non-invasive monitoring of tumor burden and treatment response across a variety of solid tumors. </p> Methods <p> In this case study, we report on&#xa0;two patients with histologically confirmed HPV + (HPV16 and HPV33) LSSCC managed with definitive chemoradiotherapy who underwent serial ctDNA monitoring prior to, during, and following treatment using an ultrasensitive multi-feature HPV whole genome sequencing liquid biopsy.</p> Results <p>In this case study, we report on&#xa0;two patients with histologically confirmed HPV + (HPV16 and HPV33) LSSCC managed with definitive chemoradiotherapy who underwent serial ctDNA monitoring prior to, during, and following treatment using an ultrasensitive multi-feature HPV whole genome sequencing liquid biopsy.</p> Conclusions <p> This report suggests that ctDNA monitoring is a feasible approach for detection and monitoring of HPV + LSSCC. We advocate for continued p16 immunohistochemistry in all squamous cell carcinomas arising in the lacrimal sac. Confirmation with HPV ISH or PCR should be performed given the potential impact on management and surveillance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating Tumor HPV DNA Kinetics for Squamous Cell Carcinoma of the Lacrimal Sac Treated with Chemoradiotherapy

  • 期刊论文

  • 发表日期：

    2026年1月30日

查看全文
  • Jonathan J. Paly,
  • William C. Faquin,
  • Ross D. Merkin,
  • Shriya Shukla,
  • Gjystina Lumaj,
  • Samuli Eldfors,
  • Qin Wang,
  • Dipon Das,
  • Daniel L. Faden

摘要

Introduction

Lacrimal sac squamous cell carcinoma (LSSCC) is the most common tumor of the rare disease subsite of the nasolacrimal system. Circulating tumor DNA (ctDNA) has emerged as a biomarker for non-invasive monitoring of tumor burden and treatment response across a variety of solid tumors.

Methods

In this case study, we report on two patients with histologically confirmed HPV + (HPV16 and HPV33) LSSCC managed with definitive chemoradiotherapy who underwent serial ctDNA monitoring prior to, during, and following treatment using an ultrasensitive multi-feature HPV whole genome sequencing liquid biopsy.

Results

In this case study, we report on two patients with histologically confirmed HPV + (HPV16 and HPV33) LSSCC managed with definitive chemoradiotherapy who underwent serial ctDNA monitoring prior to, during, and following treatment using an ultrasensitive multi-feature HPV whole genome sequencing liquid biopsy.

Conclusions

This report suggests that ctDNA monitoring is a feasible approach for detection and monitoring of HPV + LSSCC. We advocate for continued p16 immunohistochemistry in all squamous cell carcinomas arising in the lacrimal sac. Confirmation with HPV ISH or PCR should be performed given the potential impact on management and surveillance.